找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Diagnoses Without Names; Challenges for Medic Michael D. Lockshin,Mary K. Crow,Medha Barbhaiya Book 2022 Springer Nature Switzerland AG 202

[復(fù)制鏈接]
樓主: Clinton
11#
發(fā)表于 2025-3-23 13:25:59 | 只看該作者
Ever-Evolving Disease Classification Criteria for Clinical Trials and Studies: The Case of Systemic ue patient, classification and classification criteria are used to describe populations for clinical trials and studies and to create somewhat homogeneous, reproducible, and understood populations for clinical research. The development of classification criteria with high sensitivity and specificity
12#
發(fā)表于 2025-3-23 16:05:05 | 只看該作者
13#
發(fā)表于 2025-3-23 19:28:52 | 只看該作者
When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosusrials, especially those with oversight by regulatory agencies, are pure, they are not. Systemic lupus erythematosus (SLE) clinical trials suffer from some of the same issues that plague everyday clinical life. Does everyone in a clinical trial truly have SLE? Is the activity score declared in the ca
14#
發(fā)表于 2025-3-23 22:32:15 | 只看該作者
15#
發(fā)表于 2025-3-24 06:16:10 | 只看該作者
Managing and Tolerating Diagnostic Uncertaintyfor managing diagnostic uncertainty, however, this pursuit is inadequate. Diagnostic knowledge takes time to acquire, and diagnostic uncertainty is not completely curable. Furthermore, diagnostic uncertainty elicits negative psychological responses that need to be palliated, as well as positive resp
16#
發(fā)表于 2025-3-24 09:50:41 | 只看該作者
17#
發(fā)表于 2025-3-24 11:21:14 | 只看該作者
In the Box or Out of the Boxtudies in well-defined population. Inclusion and exclusion criteria may be the most important aspect of a clinical study or trial. Lumping or splitting determines which patients can ultimately use a risk stratification algorithm or a therapy. Both processes are valid; studies must be more transparent about how they have lumped or split.
18#
發(fā)表于 2025-3-24 17:54:25 | 只看該作者
19#
發(fā)表于 2025-3-24 21:32:47 | 只看該作者
20#
發(fā)表于 2025-3-25 02:09:14 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 01:18
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
苍山县| 桐柏县| 无极县| 芒康县| 敦化市| 富宁县| 西平县| 池州市| 怀安县| 柏乡县| 乡城县| 凉城县| 宝丰县| 太白县| 慈溪市| 花莲市| 略阳县| 太白县| 南昌县| 新巴尔虎右旗| 噶尔县| 华安县| 高邑县| 抚顺县| 格尔木市| 会泽县| 太谷县| 南郑县| 肃宁县| 商都县| 利津县| 岳池县| 襄汾县| 湛江市| 贡嘎县| 顺义区| 龙口市| 周口市| 昔阳县| 无锡市| 九龙城区|